127 related articles for article (PubMed ID: 30118545)
1. Synthesis of deuterium-labeled crizotinib, a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK).
Ao W; Li Y; Zhang Y
J Labelled Comp Radiopharm; 2018 Dec; 61(14):1036-1042. PubMed ID: 30118545
[TBL] [Abstract][Full Text] [Related]
2. Development and biological investigations of hypoxia-sensitive prodrugs of the tyrosine kinase inhibitor crizotinib.
Bielec B; Schueffl H; Terenzi A; Berger W; Heffeter P; Keppler BK; Kowol CR
Bioorg Chem; 2020 Jun; 99():103778. PubMed ID: 32229347
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and biological evaluations of 2-amino-4-(1-piperidine) pyridine derivatives as novel anti crizotinib-resistant ALK/ROS1 dual inhibitors.
Liu S; Jiang Y; Yan R; Li Z; Wan S; Zhang T; Wu X; Hou J; Zhu Z; Tian Y; Zhang J
Eur J Med Chem; 2019 Oct; 179():358-375. PubMed ID: 31260890
[TBL] [Abstract][Full Text] [Related]
4. N-[
Buck JR; Saleh S; Claus T; Lovly C; Hight MR; Nickels ML; Noor Tantawy M; Charles Manning H
Bioorg Med Chem Lett; 2020 Aug; 30(16):127257. PubMed ID: 32631505
[TBL] [Abstract][Full Text] [Related]
5. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.
Rodig SJ; Shapiro GI
Curr Opin Investig Drugs; 2010 Dec; 11(12):1477-90. PubMed ID: 21154129
[TBL] [Abstract][Full Text] [Related]
6. Structural basis for drug resistance mechanisms against anaplastic lymphoma kinase.
Goyal S; Jamal S; Shanker A; Grover A
J Cell Biochem; 2019 Jan; 120(1):768-777. PubMed ID: 30161279
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and evaluation of
Lin Q; Zhang Y; Fu Z; Hu B; Si Z; Zhao Y; Shi H; Cheng D
Bioorg Med Chem; 2020 Aug; 28(15):115577. PubMed ID: 32631560
[TBL] [Abstract][Full Text] [Related]
8. Discovery of 2-aminopyridines bearing a pyridone moiety as potent ALK inhibitors to overcome the crizotinib-resistant mutants.
Chen W; Guo X; Zhang C; Ke D; Zhang G; Yu Y
Eur J Med Chem; 2019 Dec; 183():111734. PubMed ID: 31569004
[TBL] [Abstract][Full Text] [Related]
9. Dose-escalation trial of the ALK, MET & ROS1 inhibitor, crizotinib, in patients with advanced cancer.
Clark JW; Camidge DR; Kwak EL; Maki RG; Shapiro GI; Chen I; Tan W; Randolph S; Christensen JG; Ozeck M; Tang Y; Wilner KD; Salgia R
Future Oncol; 2020 Jan; 16(1):4289-4301. PubMed ID: 31778074
[No Abstract] [Full Text] [Related]
10. Novel Crizotinib-GnRH Conjugates Revealed the Significance of Lysosomal Trapping in GnRH-Based Drug Delivery Systems.
Murányi J; Varga A; Gyulavári P; Pénzes K; Németh CE; Csala M; Pethő L; Csámpai A; Halmos G; Peták I; Vályi-Nagy I
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31717403
[TBL] [Abstract][Full Text] [Related]
11. Crizotinib reduces the rate of dark adaptation in the rat retina independent of ALK inhibition.
Liu CN; Mathialagan N; Lappin P; Fortner J; Somps C; Seitis G; Johnson TR; Hu W; Matsumoto D
Toxicol Sci; 2015 Jan; 143(1):116-25. PubMed ID: 25326243
[TBL] [Abstract][Full Text] [Related]
12. Next generation sequencing reveals a novel ALK G1128A mutation resistant to crizotinib in an ALK-Rearranged NSCLC patient.
Ai X; Niu X; Chang L; Chen R; Ou SI; Lu S
Lung Cancer; 2018 Sep; 123():83-86. PubMed ID: 30089600
[TBL] [Abstract][Full Text] [Related]
13. Crizotinib treatment for patients with EGFR mutation positive NSCLC that acquire cMET amplification after EGFR TKI therapy results in short-lived and heterogeneous responses.
van Veggel B; de Langen AJ; Hashemi S; Monkhorst K; Rosenberg EH; Heideman DAM; Radonic T; Smit EF
Lung Cancer; 2018 Oct; 124():130-134. PubMed ID: 30268451
[TBL] [Abstract][Full Text] [Related]
14. Structural Alterations of MET Trigger Response to MET Kinase Inhibition in Lung Adenocarcinoma Patients.
Plenker D; Bertrand M; de Langen AJ; Riedel R; Lorenz C; Scheel AH; Müller J; Brägelmann J; Daßler-Plenker J; Kobe C; Persigehl T; Kluge A; Wurdinger T; Schellen P; Hartmann G; Zacherle T; Menon R; Thunnissen E; Büttner R; Griesinger F; Wolf J; Heukamp L; Sos ML; Heuckmann JM
Clin Cancer Res; 2018 Mar; 24(6):1337-1343. PubMed ID: 29284707
[No Abstract] [Full Text] [Related]
15. Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression.
Chen RL; Zhao J; Zhang XC; Lou NN; Chen HJ; Yang X; Su J; Xie Z; Zhou Q; Tu HY; Zhong WZ; Yan HH; Guo WB; Wu YL; Yang JJ
BMC Cancer; 2018 Nov; 18(1):1171. PubMed ID: 30477470
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of ALK Tyrosine Kinase Inhibitors in Elderly Patients with Advanced ALK-Positive Non-Small Cell Lung Cancer: Findings from the Real-Life Cohort.
Bedas A; Peled N; Maimon Rabinovich N; Mishaeli M; Shochat T; Zer A; Rotem O; Allen AM; Bar J; Dudnik E;
Oncol Res Treat; 2019; 42(5):275-282. PubMed ID: 30955009
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic/pharmacodynamic modeling of crizotinib for anaplastic lymphoma kinase inhibition and antitumor efficacy in human tumor xenograft mouse models.
Yamazaki S; Vicini P; Shen Z; Zou HY; Lee J; Li Q; Christensen JG; Smith BJ; Shetty B
J Pharmacol Exp Ther; 2012 Mar; 340(3):549-57. PubMed ID: 22129595
[TBL] [Abstract][Full Text] [Related]
18. Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK).
Cui JJ; Tran-Dubé M; Shen H; Nambu M; Kung PP; Pairish M; Jia L; Meng J; Funk L; Botrous I; McTigue M; Grodsky N; Ryan K; Padrique E; Alton G; Timofeevski S; Yamazaki S; Li Q; Zou H; Christensen J; Mroczkowski B; Bender S; Kania RS; Edwards MP
J Med Chem; 2011 Sep; 54(18):6342-63. PubMed ID: 21812414
[TBL] [Abstract][Full Text] [Related]
19. Effects of Treatment with Crizotinib on Non-small Cell Lung Carcinoma with ALK Translocation in the Czech Republic.
Miloš P; Jana S; Vítězslav K; Monika Š; Leona K; Jaromír R; Renata C; Markéta Č; Andrea B; Juraj K; Michal H; Milada Z; Marek K; Helena Č; Martin S
Klin Onkol; 2018; 31(3):207-212. PubMed ID: 30441974
[TBL] [Abstract][Full Text] [Related]
20. ALK inhibitors in the treatment of advanced NSCLC.
Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F
Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
